Navigation Links
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Date:6/1/2009

SEATTLE and ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company's proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Abstract 3017: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)), in Relapsed and Refractory CLL -- Early Promising Clinical Activity

The clinical data presented at the American Society of Clinical Oncology (ASCO) are preliminary results from an ongoing Phase 1 / 2 clinical trial (#16007) of TRU-016 for the treatment of CLL and small lymphocytic leukemia (SLL). The objectives of the Phase 1 TRU-016 CLL study were to define safety and tolerability, identify a maximum tolerated dose, evaluate pharmacology and pharmacodynamics, and assess preliminary clinical activity. Patients received either one dose weekly for four weeks, or three doses the first week followed by three additional weekly doses. Patients were also able to receive up to two additional cycles if clinical benefit was observed.

At the time of the presentation, data were available for 26 patients enrolled in the Phase 1 dose escalation trial, all of whom had received an average of 6.5 prior treatments, including at least one fludarabine-containing regimen. All patients had also previously received rituximab or other anti-CD20 therapies an average of three times, either as a single agent
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
4. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
5. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
6. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
9. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LONDON , Aug. 20, 2014 Reportbuyer.com ... Global Cardiac Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... Cardiac Defibrillators in US$ Million by the following Product ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Market Report of Pralmorelin 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... WASHINGTON, Oct. 31 The following is being,issued by ... will hold a news conference about the lawsuit it ... Agriculture (USDA),to prevent the agency from allowing into the ... cattle over 30 months (OTM) of age,scheduled to begin ...
... Vice President of Scientific Affairs Dr. Randy Huffman ... Fund report, slated for,release October 31. Dr. Huffman ... WCRF,s 9:30 a.m. press conference., The American ... largest,association representing U.S. meat and poultry packers and ...
Cached Medicine Technology:R-CALF United Stockgrowers of America: 'Fighting for the U.S. Cattle Producer' 2
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced ... donation drive that benefits the animal shelter and rescue communities. ... with the Humane Society of the United States’ Animal Shelter ... , As part of their participation, Park Cities Pet Sitter ... the Presents 4 Pets drive from their client base, as ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
(Date:8/20/2014)... novel approach to treating cancer - using Botox. A ... Science Translational Medicine shows that cancer growth could ... that are linked to cancer stem cells. The approach ... the treatment cheap, safe and efficient. The researchers have ... soon start testing on humans. , The nervous system ...
(Date:8/20/2014)... YORK -- The most common cause of endophthalmitis, a ... eye surgery, and eye injections, are the well-known ... strains, according to a study published in the August ... review of 25 years of cases at New York ... , The new study found that gram-positive bacteria, which ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Treating gastric cancer -- with Botox 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3
... Delcath Systems, Inc. (Nasdaq: DCTH ... proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment ... James F. Pingpank will present at The Sixth International ... City on March 13-14, 2009. (Logo: ...
... CDC says more emphasis needed on tobacco-control programs , , ... marketing and promotion and tobacco-control programs are among the ... in some states than others, according to a new ... Prevention. , About 28 percent of adults in Kentucky ...
... Safe to Eat and Who,s Most At RiskLANSING, Ill., ... safety legislation under debate in the U.S. Senate and ... Americans are more concerned than ever when it comes ... unaware of the long-term side effects of Salmonella, one ...
... Choosing to have aggressive brain surgery after suffering a ... them to live longer, according to research by neurologists ... findings should help patients and families put into perspective ... to make whether putting a patient through aggressive ...
... citizens and the European medical industry and facilitate the ... the bedside. For Europe and for the rest of ... for the quality of life of individuals and the ... achieve this important objective, the European Medical Research Councils ...
... condition will affect more than 78 million U.S. ... lenses can resolve their vision needs to avoid ... manufacturer of the #1 multifocal lens design, has ... goal of raising U.S. awareness of presbyopia and ...
Cached Medicine News:Health News:Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City 2Health News:Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City 3Health News:Smoking Isn't Falling as Fast as Officials Hoped: Report 2Health News:Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning 2Health News:Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning 3Health News:Weighing the options after life-altering stroke 2Health News:Weighing the options after life-altering stroke 3Health News:Weighing the options after life-altering stroke 4Health News:Better health and prosperity in Europe via improved clinical research 2Health News:Bausch & Lomb Launches Multi-Tiered U.S. Consumer Education Initiative to Raise Awareness of Presbyopia 2Health News:Bausch & Lomb Launches Multi-Tiered U.S. Consumer Education Initiative to Raise Awareness of Presbyopia 3
... you need spirometry tests,performed ... at a patients,home, the ... the healthcare practitioner on ... allows easy,navigation, while Sensaires ...
ASAP™ Automated Biopsy System with Channel Cut™ Needle....
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
Medicine Products: